April 2008
Worldwide Biotech;Apr2008, Vol. 20 Issue 4, p6
Trade Publication
The article reports that global independent biopharmaceutical company Debiopharm Group in Lausanne, Switzerland, has received a recommendation to continue its Phase II BRAINz study with Debio 9902 sustained release (SR) for the treatment of Alzheimer's disease without modification. According to David Wilkinson of Moorgreen Hospital, the recommendation confirms the safety profile of Debio 9902 SR, a novel acetylcholinesterase (AChE) inhibitor.


Related Articles

  • Debiopharm and Pharmaleads sign licensing agreement.  // PharmaWatch: Biotechnology;Jan2009, Vol. 8 Issue 1, p17 

    The article reports on an exclusive license agreement signed by Debiopharm Group for the development, registration and commercialization of a small molecule called Debio 0827 or PL37 in the U.S. The agreement allows Debiopharm to make an up-front payment to Pharmaleads. It is revealed that Debio...

  • Pretreatment with Huperzine A Protects Acetylcholinesterase in the Rat Brain Against Inhibition by VX and Russian VX. Karasova, Jana Zdarova; Bajgar, Jiri; Novotny, Ladislav; Kuca, Kamil // Letters in Drug Design & Discovery;Dec2009, Vol. 6 Issue 8, p563 

    Organophosphate nerve agents are still considered as potential threats in both military and terrorism situations. They are potent irreversible inhibitors of acetylcholinesterase in central and also in peripheral compartment. Huperzine A (Hup A) is a reversible AChE inhibitor that crosses the...

  • Regular Use of Acetylcholinesterase Inhibitors, Memantine Linked to Reduced Mortality in Alzheimer's Disease. Hughes, Debra // Neurology Reviews;Aug2007, Vol. 15 Issue 8, p58 

    The article presents a study which investigates the correlation between the use of acetylcholinesterase inhibitors and memantine and the mortality rate in Alzheimer's disease. Randomize clinical trials of acetylcholinesterase inhibitors and memantine have showed efficacy for maintaining or...

  • Donepezil: A Review of Pharmacological Characteristics and Role in the Management of Alzheimer Disease. Jelic, Vesna; Darreh-Shori, Taher // Clinical Medicine Insights: Therapeutics;2010, Issue 2, p771 

    Donepezil is a potent, selective, noncompetitive, and rapidly reversible inhibitor of acetylcholinesterase (AChEI) licensed for the treatment of Alzheimer disease (AD); and is the first and only AChEI licensed for the treatment of severe AD. Its efficacy as monotherapy, or in combination with...

  • Debiopharm offers encouraging data for Alzheimer's treatment.  // PharmaWatch: CNS;Jul2007, Vol. 6 Issue 7, p7 

    No abstract available.

  • CLINIC ROUNDUP.  // BioWorld Today;4/29/2008, Vol. 19 Issue 83, p4 

    This section offers news briefs on clinical trials as of April 29, 2008. Cara Therapeutics Inc. has begun a Phase I clinical trial of its long-acting peripheral kappa opioid receptor agonist, CR845. The first dosing regime in a Phase I study of the HuCAL-derived antibody MOR103 has been...

  • Other News To Note.  // BioWorld International;8/29/2012, Vol. 17 Issue 35, p2 

    This section offers news briefs related to clinical trials as of August 2012. Phase I pharmacokinetic data for ActoGeniX's AG013 oral rinsing solution for the prevention of oral mucositis has showed that the liver AG013 bacteria adhered to the buccal mucosa and secreted protein locally. A Phase...

  • CURIS & DEBIOPHARM BEGIN PHASE I DOSE FINDING STUDY.  // Worldwide Biotech;Nov2013, Vol. 25 Issue 11, p6 

    The article reports on the move of the pharmaceutical companies Curis Inc. and Debiopharm Group to start the open-label, multicenter Phase I dose-finding study of its heat shock protein 90 (HSP90) inhibitor, Debio 0932, along with everolimus (Afinitor). It details the goal of the study, designed...

  • Clinic Roundup.  // BioWorld Today;7/25/2012, Vol. 23 Issue 143, p10 

    This section offers news briefs on the pharmaceutical industry. Results of a Phase III trial involving Amarin Corp. plc's AMR101 are available electronically through "The American Journal of Cardiology." BioCryst Pharmaceuticals Inc. has released Phase IIb trial results showing the safety and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics